AiRuiKa (camrelizumab) / CG Invites, Jiangsu Hengrui Pharma, HLB Bio Group, NPO Petrovax - LARVOL DELTA

Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC) (clinicaltrials.gov) - P=N/A | N=2000 | Not yet recruiting | Sponsor: Qun Zhao

New trial • Real-world evidence • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial. (PubMed, BMJ) - P3 | "The addition of camrelizumab to concurrent chemoradiotherapy and as a maintenance treatment improved progression-free survival among patients with high risk nasopharyngeal carcinoma after induction chemotherapy."

Clinical • Journal • P3 data • Epstein-Barr Virus Infections • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer (clinicaltrials.gov) - P2 | N=19 | Not yet recruiting | Sponsor: Beijing Friendship Hospital

New P2 trial • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Rectal Cancer • Solid Tumor

A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond. (clinicaltrials.gov) - P2 | N=68 | Not yet recruiting | Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine

New P2 trial • Colorectal Cancer • Oncology • Solid Tumor

HLB advances China review of Rivoceranib combo as US resubmission proceeds (Chosun Biz) - "HLB said on the 2nd that its Chinese partner Jiangsu Hengrui Pharmaceuticals recently received a notice from China's National Medical Products Administration (NMPA) that it has begun the substantive review of the combination therapy of 'Rivoceranib, Camrelizumab, and transarterial chemoembolization (TACE)' for patients with unresectable hepatocellular carcinoma. The application is based on the results of a phase 3 clinical trial conducted with 423 patients at 34 medical institutions in China."

China filing • Hepatocellular Cancer

Camrelizumab plus apatinib in patients with advanced or refractory chordoma: A single-arm, open-label, phase 2 trial. (ASCO 2025) - P2 | "The combination of camrelizumab and apatinib demonstrated promising efficacy and manageable toxicity in chordoma treatment. Furthermore, CDKN2A alterations (CND or HD) were associated with poorer outcomes, providing a potential biomarker for therapeutic stratification."

Clinical • IO biomarker • Metastases • P2 data • Chordoma • CDKN2A

MA-GC-II-019: Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer (clinicaltrials.gov) - P2 | N=80 | Active, not recruiting | Sponsor: Ruijin Hospital | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial. (ASCO 2025) - P2 | "Stage 1 results of CAP 03-NEO demonstrated the potential of neoadjuvant camrelizumab, apatinib and temozolomide in pts with resectable stage II/III AM. The pNR result support advancing to stage 2 to further assess the efficacy and safety of this regimen in pts with stage III disease."

Clinical • Constipation • Gastroenterology • Gastrointestinal Disorder • Melanoma • Oncology • Solid Tumor

A case report of breast cancer recurrence with cystitis: the impact of immune checkpoint inhibitor therapy on the incidence of cystitis. (PubMed, Immunotherapy) - "A 51-year-old female with recurrent breast cancer (TNBC-like, IM subtype) following a 10-year disease-free interval underwent treatment with a paclitaxel-based chemotherapy regimen combined with camrelizumab. This case highlights a rare presentation of immune-related cystitis associated with ICI therapy in recurrent breast cancer. ICIs may increase cystitis risk through immune-mediated mechanisms, although the underlying pathophysiology remains unclear, warranting further investigation."

Checkpoint inhibition • Journal • Breast Cancer • Nephrology • Oncology • Solid Tumor • Triple Negative Breast Cancer

Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy. (PubMed, BMC Cancer) - "In summary, early clearance of plasma EBV DNA load and high levels of lytic EBV genes were associated with better clinical outcome in patients with RM-NPC receiving anti-PD-1 monotherapy."

Clinical data • Journal • Metastases • Monotherapy • Epstein-Barr Virus Infections • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma (GlobeNewswire) - "The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 23, 2026....Elevar on Jan. 23, 2026, submitted the NDA for rivoceranib, while Hengrui Pharma submitted a biologics license application (BLA) for camrelizumab....In Elevar’s global Phase 3 CARES-310 study, the camrelizumab plus rivoceranib combination therapy achieved a median overall survival of 23.8 months in patients with uHCC, representing the longest overall survival reported to date among first-line treatments for uHCC."

FDA filing • PDUFA • Hepatocellular Cancer

Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial. (PubMed, Eur J Cancer) - P2 | "NCRCN regimen was a promising treatment strategy with a high surgical conversion rate in initially inoperable patients with LAESCC. TRIAL REGISTRATION CLINICALTRIALS."

Journal • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Disorder • Hematological Disorders • Neutropenia • Oncology • Squamous Cell Carcinoma • CD8 • FOXP3

Long-Term Outcomes of Brain Radiotherapy Combined With Camrelizumab and Platinum-Doublet Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) with Brain Metastases: 3-Year Updated Results of the Phase 2 C-Brain Trial (ELCC 2026) - No abstract available

Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

THE EFFICACY AND SAFETY OF PD-1 MONOCLONAL ANTIBODY IN THE TREATMENT OF HEMOPHAGOCYTIC SYNDROME:SYSTEMATIC REVIEW (EBMT 2026) - "Data regarding the efficacy and safety of PD-1 monoclonal antibodies used (such as sintilimab, nivolumab, camrelizumab, and tislelizumab) in both pediatric and adult patients with HLH were included...In pediatric patients (aged 3–7 years) with CAEBV and r/r EBV-HLH, sintilimab (3mg/kg, once every 3-4 weeks, monotherapy or combined with L-DEP regimen (pegaspargase, liposomal doxorubicin, etoposide, and high-dose methylprednisolone)) induced partial or complete clinical remission and significantly reduced plasma EBV-DNA levels (>50%), successfully serving as a bridge to allogeneic hematopoietic stem cell transplantation (HSCT) in some cases...Furthermore, novel combinations with ruxolitinib, venetoclax, or thalidomide achieved rapid clinical remission in EBV-HLH... PD-1 monoclonal antibodies demonstrate significant therapeutic potential as salvage therapy for r/r EBV-HLH, effectively reducing viral loads and inducing remission. However, immune checkpoint inhibition acts..."

Clinical • Review • Bone Marrow Transplantation • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Lymphoma • Natural Killer/T-cell Lymphoma • Rare Diseases • T Cell Non-Hodgkin Lymphoma

Sequential anlotinib and camrelizumab combination therapy achieves exceptional survival in multi-driver mutated, TMB-low/PD-L1-low/MSS pulmonary sarcomatoid carcinoma: case report and literature review. (PubMed, Front Immunol) - "This approach resulted in unprecedented survival outcomes: the 72-month overall survival dramatically exceeds the median OS of less than 12 months reported for advanced PSC, and the patient maintained a progression-free survival of over 37 months on combination therapy, surpassing historical PFS benchmarks. This case provides a clinically actionable framework for managing multi-driver mutated, immunoresistant PSC."

Biomarker • IO biomarker • Journal • Review • Tumor mutational burden • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Sarcoma • Solid Tumor • ALK • PD-L1 • PTEN • ROS1 • STK11 • TMB • TSC2

Analysis of the efficacy of camrelizumab/cetuximab neoadjuvant therapy in patients with loco-regionally advanced laryngeal and hypopharyngeal cancer and the prognostic value of NLR/SII. (PubMed, World J Surg Oncol) - "In patients with loco-regionally advanced laryngeal and hypopharyngeal carcinoma, combining camrelizumab with TP chemotherapy demonstrates favorable short-term efficacy and laryngeal preservation rates while maintaining an acceptable safety profile. The inflammatory immune markers SII and NLR have valuable predictive utility in this patient population."

Journal • Head and Neck Cancer • Hypopharyngeal Cancer • Laryngeal Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

Exploratory phase II trial of camrelizumab (an anti-PD-1 antibody) combined with apatinib (a VEGFR-2 inhibitor) and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis (SABCS 2025) - P2 | "The treatment regimen consisted of camrelizumab (200 mg intravenously every 2 weeks, 12 cycles), apatinib (250 mg orally daily), and alternating chemotherapy [nab-paclitaxel (d1, 8, 15 every 4 weeks) for 4 cycles and epirubicin plus cyclophosphamide (every 2 weeks) for 4 cycles]. From June 2023 to April 2024, 35 patients were enrolled, of whom 1 patient withdrew due to adverse reaction intolerance. In conclusion, camrelizumab and apatinib combined with chemotherapy have good clinical efficacy and good safety as neoadjuvant treatments for stage II-III TNBC, warranting further investigation and potential clinical application. This innovative dual-score system stratifies pretreatment prognosis (PRPscore) and dynamically evaluates therapeutic efficacy (EAscore), enabling precision neoadjuvant optimization."

Biomarker • Clinical • IO biomarker • P2 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD4 • CXCL1 • IL17A • IL18 • MMP7 • PD-L1 • TP53

Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial. (PubMed, JAMA Oncol) - P3 | "In this secondary analysis of a randomized clinical trial, the addition of camrelizumab to chemotherapy produced statistically significant and clinically meaningful 5-year OS benefits compared with chemotherapy alone in the first-line treatment of RM-NPC. These findings provided the first 5-year evidence supporting the benefit of PD-1-based chemoimmunotherapy in this setting."

Clinical • Journal • Epstein-Barr Virus Infections • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • PD-L1

Inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: a prospective, single-arm, phase 2 study. (PubMed, BMC Med) - P2 | "The combination of inetetamab, camrelizumab, and utidelone demonstrated promising efficacy and a manageable safety profile in heavily pretreated patients with HER2-positive MBC. These findings support this regimen as a viable treatment option in this setting and warrant further investigation in randomized controlled trials."

Journal • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Pain • Solid Tumor • HER-2

A Multicenter, Randomized Phase II Study Evaluating Thalidomide for the Prevention of RCCEP in Advanced NSCLC Treated with First-Line Camrelizumab Plus Chemotherapy (ELCC 2026) - No abstract available

Clinical • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor

Neoadjuvant PD-1 inhibitor plus chemotherapy and radiotherapy for potentially resectable locally advanced esophageal squamous cell carcinoma with esophageal fistula or high-risk for esophageal fistula: a single-arm phase I trial (ChiCTR) - P1 | N=9 | Recruiting | Sponsor: Sichuan Cancer Hospital; Sichuan Cancer Hospital

New P1 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Disorder • Oncology • Squamous Cell Carcinoma

Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Henan Cancer Hospital | Recruiting ➔ Active, not recruiting

Enrollment closed • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416) (clinicaltrials.gov) - P=N/A | N=244 | Completed | Sponsor: First Hospital of China Medical University | Recruiting ➔ Completed

Trial completion • Hepatocellular Cancer • Oncology • Solid Tumor • Thrombosis

Perioperative camrelizumab plus rivoceranib in resectable hepatocellular carcinoma (CARES-009): A randomized, multicenter, phase III trial (ESMO 2025) - P2/3 | "Grade ≥3 treatment-related adverse events occurred in 37.6% of patients in the perioperative group. Conclusions Perioperative camrelizumab plus rivoceranib significantly improved EFS and MPR compared with surgery alone in patients with resectable HCC at intermediate or high-risk of recurrence."

Clinical • P3 data • Hepatocellular Cancer • Oncology • Solid Tumor

Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial. (PubMed, Lancet Oncol) - P2 | "These findings highlight the potential clinical benefits of using molecular subtype-based treatment optimisation in patients with triple-negative breast cancer, suggesting a path for further clinical investigation. Phase 3 randomised clinical trials assessing the efficacy of subtyping-based regimens are now underway."

Journal • P2 data • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • Neutropenia • Oncology • Solid Tumor • Triple Negative Breast Cancer • AR • HER-2